20 May 2021
The revision of the EU legislation on medicines for rare diseases and for children is one of the key actions of the Pharmaceutical Strategy for Europe. Our joint policy dialogue organised with the European Society for Paediatric Oncology, European Fair Pricing Network and the Association of European Cancer Leagues discussed concrete recommendations to deliver optimal treatment for children and those suffering from rare diseases, as ”one-size-fits-all” incentives do not lead to a sustainable and equitable pharmaceutical system.
On Social Media
To the needs of patients with orphan diseases we should involve patients and physicians in the research agenda and we need more studies. We should set up a European research and technical infrastructure for easy to conduct and less costly randomised trials. #LetsTalkAccess— IQWiG (@iqwig) May 20, 2021